Bank Rakyat unveils Akaun-i eGold for online gold trading
The account allows customers to invest in 999.9 fine gold, accredited by the London Bullion Market Association (LBMA), starting from as low as RM10.
It also offers real-time buying and selling prices, along with the potential to enjoy more competitive spreads between purchase and selling prices.
Customers also have the option to convert their digital gold balance in the Akaun-i eGold into physical gold, available in denominations from 0.5 grams up to 100 grams.
The gold can be delivered directly to the customer's preferred address through a dedicated delivery service.
Bank Rakyat in a statement said the launch of the new product reflects its ongoing commitment to helping customers diversify their financial portfolios by including gold as an alternative investment, or as a flexible and long-term savings solution.
"Alongside improving access to gold ownership with a low entry point, this product supports the Bank's ongoing efforts to offer inclusive financial services.
"It allows people from all walks of life to participate in gold transactions, buying, selling and converting digital investments into physical gold, to help them reach their financial goals with ease," it added.
To start investing through Akaun-i eGold, customers must have a Bank Rakyat Current Account-i, Savings Account-i or Investment Account-i, along with access to iRakyat online banking.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
39 minutes ago
- New Straits Times
Honor continues Malaysia expansion, unveils 100th outlet in KLCC
KUALA LUMPUR: HONOR Malaysia has reached a milestone with the opening of its 100th retail store in Suria KLCC. The opening marks four years of rapid expansion since the brand's debut in the Malaysian market. HONOR South Pacific president Justin Li said: "Opening our 100th store at such a prestigious location is a proud moment for all of us at HONOR. "It represents our commitment to the Malaysian market and the strong support we've received from local consumers. "We're excited to continue growing and delivering cutting-edge technology that truly meets users' needs," he added. According to the latest third-party survey data, HONOR has secured market leadership in the mid-premium smartphone segment, with one in every four devices sold in the RM1,500 to RM3,000 range now bearing the HONOR brand. HONOR plans to invest RM10 million annually into expanding its retail presence and enhancing in-store experiences across Malaysia. The funds will be used to upgrade customer engagement zones, integrate smart technologies and create more immersive product trial areas. EXPANDING INDUSTRY Since opening its first service centre in 2022, HONOR Malaysia has launched 18 official centres across the country. It aims to increase this number to 22 to 25 by the end of the year, giving it the largest official tech service network in Malaysia. Despite HONOR products being known for low repair rates, the company said it remains focused on continuous improvement in customer care and post-purchase service. EXCLUSIVE OFFERS To mark the KLCC launch on Saturday, June 28, the first 100 walk-in customers received limited-edition gifts and exclusive discounts. The event also featured product experience zones where visitors explored HONOR's latest innovations, including the Magic7 Pro and its new range of foldable devices. These hands-on showcases highlighted HONOR's cutting-edge design, seamless functionality, and user-first philosophy.
New Straits Times
5 hours ago
- New Straits Times
How Share-Backed Loans Can Boost the Economy
AS Malaysia moves towards becoming a high-income nation, financial innovation will play a crucial role in enabling inclusive and sustainable growth. While conversations around financial inclusion often focus on access to banking, microcredit, or insurance, a lesser-known but equally important development is emerging quietly in the background: share-backed financing. Put simply, share-backed loans allow investors to unlock liquidity from their existing stock portfolios without needing to sell off assets. In doing so, they preserve long-term wealth while gaining access to short-term capital, whether to fund a business, manage personal cash flow, or seize timely investment opportunities. This form of financing offers investors flexibility and choice, especially during times when traditional lending options may not be readily accessible. And because it's structured around assets the investor already owns, it creates a more efficient pathway to capital. As someone working in the field of share financing, I've seen first hand how this model can bring meaningful benefits to Malaysians across different walks of life. We've seen investors use it to get new businesses off the ground, to cover cash flow shortfalls during uncertain periods, and even to strategically reallocate funds while maintaining a long-term investment position. These are real financial decisions, made by ordinary investors, who are simply looking for better tools to manage their wealth. What's promising is that this model is gaining traction among not just high-net-worth individuals, but also retail investors, especially as more Malaysians participate in the stock market and build up equity portfolios. The idea that your shares can work harder for you, without needing to be sold, is a shift that resonates with investors seeking both growth and stability. This is especially significant given that Bursa Malaysia hit a new record of more than RM2 trillion in 2024 in equities market capitalisation. If just 10 per cent of those retail investments were leveraged through regulated share-backed loans, it could translate into a substantial injection of liquidity into the local economy. Such capital mobilisation has real multiplier effects, from funding new businesses to boosting consumer spending, all of which contribute to national economic growth. In the context of Malaysia's broader economic ambitions, this matters. When investors have the tools to turn financial assets into productive capital, it can lead to stronger domestic investment, greater entrepreneurial activity, and more robust financial resilience. At a time when small businesses need easier access to funding and individuals are seeking smarter ways to manage money, share-backed loans can play a complementary role alongside existing financial services. When built on a Shariah-compliant foundation, it creates an ethical and inclusive offering for investors who want to align their financial decisions with Islamic principles. This is a clear advantage for Malaysia, as we continue to innovate within a regulatory environment that supports both conventional and Islamic finance. Of course, any financial innovation must come with safeguards. It is crucial that investors understand the mechanics and risks involved, including what happens if share prices move against expectations. Transparency, investor education and responsible lending practices are key to ensuring that share-backed loans empower the people who use them. The success of this model will depend on how well the ecosystem can balance innovation with protection. Licensed financial providers must be held to high standards of compliance, data security, and ethical conduct. And as this space grows, it's important that regulators and industry players work together to evolve the guardrails around share financing in a way that fosters long-term trust. Ultimately, the future of Malaysia's economy rests not only on macroeconomic strategies but also on the tools we give individuals to participate more meaningfully in financial growth. Share-backed loans offer one such tool - one that's grounded in ownership, powered by choice, and positioned to support the aspirations of a new generation of investors. In moving forward, we must ensure that financial innovation is not just about technology, but about relevance, giving people real options to improve their financial outcomes, and in doing so, creating ripple effects that support the wider economy. *The writer is the head of operations of Saham2u. The views expressed here are her own.
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and outlines key terms for a future supply agreement for GMP-compliant Monepantel Provides a clear pathway for accelerated global commercialisation of NUZ-001[1] and significantly de-risks future global regulatory approval processes The license agreement represents the first step in formalising Neurizon's relationship with Elanco, with the next step focused on finalising a supply agreement expected H2 CY 2025 MELBOURNE, Australia, July 2, 2025 /PRNewswire/ — Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ('Neurizon' or 'the Company'), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has executed an exclusive global license agreement with Elanco Animal Health Incorporated (Elanco; NYSE: ELAN) and affiliates for Monepantel, the active pharmaceutical ingredient in NUZ-001, Neurizon's lead investigational therapy in development for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases in humans. This license agreement represents a critical inflection point for Neurizon, further strengthening the Company's strategic outlook for the development, manufacturing and potential future commercialisation of NUZ-001. It also significantly supports the Company's regulatory foundations, providing ongoing access to critical animal safety data and manufacturing data, key pillars required to support future clinical trials, potential regulatory approvals and global market entry. Dr. Michael Thurn, Managing Director and Chief Executive Officer, commented: 'This license agreement with Elanco marks a watershed moment in Neurizon's journey to become a leader in the accelerated development of treatments for neurodegenerative diseases. This strategic milestone provides exclusive access to a comprehensive package of non-clinical studies and manufacturing data, dramatically reducing near-term development costs and accelerating development timelines. All of this is in exchange for a nominal up-front payment, small back-ended regulatory approval and commercial sale milestones and single-digit royalty payments on future global net sales. Neurizon is now well-positioned to accelerate the path to market and advance new treatment options for people affected by devastating neurodegenerative diseases.' Mr. Sergio Duchini, Non-Executive Chairman, commented: 'On behalf of the Board, I am pleased to endorse this landmark agreement with Elanco, which represents a strategically significant step forward for Neurizon. This agreement not only strengthens our clinical and regulatory position but also reflects our strong commitment to accelerating the development of meaningful therapies for people living with neurodegenerative diseases. We are also very happy to be making this important step in formalising our relationship with Elanco and look forward to building on this foundation as we progress towards finalising a supply agreement later this year.' Key Terms of the Licensing Agreement: Exclusive Global Rights: Neurizon is granted exclusive global rights to Elanco's data package and related intellectual property for monepantel to develop and commercialise NUZ-001 and its related compounds for the treatment, palliation, prevention, or cure of neurodegenerative diseases in humans. Upfront Payment: A nominal upfront licensing fee is payable to Elanco upon execution of the agreement[2]. Milestone Payments: Total Development milestone payments for the initial and subsequent licensed products, indications, or presentations of US$9.75 million and US$5.2 million, respectively. Elanco will also be eligible for milestone payments of up to US $65 million based on sales milestones[3]. Royalties: Elanco will receive tiered single-digit royalties on global net sales of licensed products. Supply: The agreement outlines certain key terms, including duration and price, for the conclusion of a Supply Agreement. Supply Agreement Neurizon and Elanco remain focused on finalising a supply agreement, with a follow-up announcement anticipated in H2 CY 2025. This next phase of the collaboration is expected to provide Neurizon with long-term, scalable source of GMP-compliant monepantel to support ongoing clinical development, regulatory submissions, and future global commercialisation of NUZ-001. -ENDS- This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited. About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. Neurizon® is a registered trademark of Neurizon Therapeutics Limited [1] NUZ-001 is Neurizon Therapeutics formulation of monepantel for use in neurodegeneration applications. [2] The amount is not material to Neurizon's current cash position [3] If triggered, the sales milestone payments will not fall due until six months after the first commercial sale. The remaining regulatory and commercial milestone payments will become due 30 days after the relevant milestone is met.
